Utilization of Specific Treatments in Medical Oncology Offices

This chapter explores the extent to which specific treatments, such as Clistimab, are being utilized by general medical oncologists in the community. It discusses the adoption of these treatments in larger oncology groups with hospital affiliations, the availability and use of Tizalizumab, the comparison of El Renata MAB to Tclistemab, and the development of a fourth BCMA driven bi-specific antibody called Lindvo Seltamab.